LeonaBio, Inc. Common Stock

LONA

Market cap $25.8M

Athira Pharma Inc. (NASDAQ: ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.

Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)

Seattle-area biotech company Athira Pharma agreed to pay $4.